Free Trial
→ [Action Required] Claim Your FREE IRS Loophole Guide (From Colonial Metals) (Ad) Buy ALT Stock  Free ALT Stock Alerts

Altimmune (ALT) Financials

Altimmune logo
$4.94 -0.03 (-0.50%)
As of 10:29 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Altimmune

Annual Income Statements for Altimmune

This table shows Altimmune's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -85 -88 -95
Consolidated Net Income / (Loss)		 -85 -88 -95
Net Income / (Loss) Continuing Operations		 -85 -88 -95
Total Pre-Tax Income 		-85 -88 -95
Total Operating Income		 -88 -96 -103
Total Gross Profit		 -0.07 0.43 0.02
Total Revenue		 -0.07 0.43 0.02
Operating Revenue		 -0.07 0.43 0.02
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 88 96 103
Selling, General & Admin Expense		 17 18 21
Research & Development Expense		 71 66 82
Impairment Charge		 0.00 12 0.00
Total Other Income / (Expense), net		 2.83 7.48 8.11
Interest Expense		 0.01 0.04 0.01
Interest & Investment Income		 2.87 7.35 8.07
Other Income / (Expense), net		 -0.03 0.17 0.05
Basic Earnings per Share		 ($1.81) ($1.66) ($1.34)
Weighted Average Basic Shares Outstanding		 46.93M 53.25M 71.00M
Diluted Earnings per Share		 ($1.81) ($1.66) ($1.34)
Weighted Average Diluted Shares Outstanding		 46.93M 53.25M 71.00M
Weighted Average Basic & Diluted Shares Outstanding		 49.28M 70.90M 77.01M

Quarterly Income Statements for Altimmune

This table shows Altimmune's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -24 -22 -20 -16 -21 -32 -24 -25 -23 -23
Consolidated Net Income / (Loss)		 -24 -22 -20 -16 -21 -32 -24 -25 -23 -23
Net Income / (Loss) Continuing Operations		 -24 -22 -20 -16 -21 -32 -24 -25 -23 -23
Total Pre-Tax Income 		-24 -22 0.00 0.00 -21 -68 0.00 0.00 -23 -72
Total Operating Income		 -25 -23 -22 -18 -23 -34 -27 -27 -25 -25
Total Gross Profit		 0.00 -0.11 0.02 0.01 0.36 0.04 0.01 0.01 0.01 0.01
Total Revenue		 0.00 -0.11 0.02 0.01 0.36 0.04 0.01 0.01 0.01 0.01
Operating Revenue		 - - 0.02 0.01 0.36 0.04 0.01 0.01 0.01 0.01
Total Operating Expenses		 25 23 22 18 23 34 27 27 25 25
Selling, General & Admin Expense		 4.49 3.81 4.53 4.76 4.51 4.33 5.31 5.60 4.97 5.09
Research & Development Expense		 20 19 17 13 18 17 21 21 20 20
Total Other Income / (Expense), net		 1.04 1.43 1.69 1.95 1.87 1.98 2.40 2.11 1.92 1.69
Interest & Investment Income		 1.05 1.47 1.67 1.84 1.88 1.96 2.41 2.18 1.91 1.57
Other Income / (Expense), net		 0.05 -0.22 0.02 0.11 0.01 0.02 -0.01 -0.08 0.02 0.12
Basic Earnings per Share		 ($0.48) ($0.47) ($0.40) ($0.32) ($0.39) ($0.55) ($0.34) ($0.35) ($0.32) ($0.33)
Weighted Average Basic Shares Outstanding		 49.29M 46.93M 50.13M 50.69M 53.63M 53.25M 70.80M 70.92M 71.08M 71.00M
Diluted Earnings per Share		 ($0.48) ($0.47) ($0.40) ($0.32) ($0.39) ($0.55) ($0.34) ($0.35) ($0.32) ($0.33)
Weighted Average Diluted Shares Outstanding		 49.29M 46.93M 50.13M 50.69M 53.63M 53.25M 70.80M 70.92M 71.08M 71.00M
Weighted Average Basic & Diluted Shares Outstanding		 49.16M 49.28M 49.29M 52.69M 53.73M 70.90M 70.90M 71.07M 71.12M 77.01M

Annual Cash Flow Statements for Altimmune

This table details how cash moves in and out of Altimmune's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents		 -79 24 -98
Net Cash From Operating Activities		 -63 -76 -80
Net Cash From Continuing Operating Activities		 -63 -76 -80
Net Income / (Loss) Continuing Operations		 -85 -88 -95
Consolidated Net Income / (Loss)		 -85 -88 -95
Depreciation Expense		 0.49 0.48 0.24
Amortization Expense		 -0.70 -2.47 -3.85
Non-Cash Adjustments To Reconcile Net Income		 8.14 23 14
Changes in Operating Assets and Liabilities, net		 14 -8.27 4.48
Net Cash From Investing Activities		 -73 14 -28
Net Cash From Continuing Investing Activities		 -73 14 -28
Purchase of Property, Plant & Equipment		 -0.13 -0.05 0.00
Purchase of Investments		 -73 -89 -116
Sale and/or Maturity of Investments		 0.00 102 87
Net Cash From Financing Activities		 57 86 10
Net Cash From Continuing Financing Activities		 57 86 10
Issuance of Common Equity		 56 87 10
Other Financing Activities, net		 0.43 -0.71 -0.25

Quarterly Cash Flow Statements for Altimmune

This table details how cash moves in and out of Altimmune's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 -8.39 -16 -6.41 -2.33 -15 48 -56 -22 -26 5.45
Net Cash From Operating Activities		 -15 -17 -19 -19 -20 -17 -16 -18 -27 -18
Net Cash From Continuing Operating Activities		 -15 -17 -19 -19 -20 -17 -16 -18 -27 -18
Net Income / (Loss) Continuing Operations		 -24 -22 -20 -16 -21 -32 -24 -25 -23 -23
Consolidated Net Income / (Loss)		 -24 -22 -20 -16 -21 -32 -24 -25 -23 -23
Depreciation Expense		 -0.14 0.46 0.13 0.12 0.12 0.11 0.11 0.06 0.04 0.03
Amortization Expense		 - - -0.48 -0.63 -0.67 -0.70 -0.98 -1.07 -0.98 -0.82
Non-Cash Adjustments To Reconcile Net Income		 2.08 2.11 2.66 2.67 2.71 15 3.66 4.38 3.07 3.24
Changes in Operating Assets and Liabilities, net		 6.53 2.48 -1.63 -5.49 -1.97 0.82 5.26 3.16 -6.40 2.46
Net Cash From Investing Activities		 -25 0.98 13 3.99 4.40 -7.96 -40 -3.70 1.20 14
Net Cash From Continuing Investing Activities		 -25 0.98 13 3.99 4.40 -7.96 -40 -3.70 1.20 14
Purchase of Investments		 -25 1.02 -21 -22 -12 -34 -54 -23 -26 -13
Sale and/or Maturity of Investments		 - - 35 26 16 26 14 20 27 27
Net Cash From Financing Activities		 32 -0.04 -0.30 13 0.59 73 -0.26 -0.05 0.27 10
Net Cash From Continuing Financing Activities		 32 -0.04 -0.30 13 0.59 73 -0.26 -0.05 0.27 10
Issuance of Common Equity		 32 - 0.14 13 0.59 73 0.17 - 0.13 9.99
Other Financing Activities, net		 0.16 -0.04 -0.44 -0.29 -0.00 0.02 -0.43 -0.05 0.14 0.09

Annual Balance Sheets for Altimmune

This table presents Altimmune's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets		 207 211 139
Total Current Assets		 193 210 137
Cash & Equivalents		 111 135 37
Restricted Cash		 0.03 0.04 0.04
Short-Term Investments		 74 63 95
Accounts Receivable		 0.17 1.11 0.54
Prepaid Expenses		 5.36 6.92 2.20
Other Current Assets		 2.37 3.74 2.57
Plant, Property, & Equipment, net		 1.08 0.65 0.41
Total Noncurrent Assets		 13 0.36 1.64
Other Noncurrent Operating Assets		 0.62 0.36 1.64
Total Liabilities & Shareholders' Equity		 207 211 139
Total Liabilities		 22 17 16
Total Current Liabilities		 17 12 10
Accounts Payable		 4.80 2.07 0.21
Accrued Expenses		 12 10 10
Total Noncurrent Liabilities		 4.58 4.40 5.33
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 185 194 124
Total Preferred & Common Equity		 185 194 124
Total Common Equity		 185 194 124
Common Stock		 568 665 690
Retained Earnings		 -378 -466 -561
Accumulated Other Comprehensive Income / (Loss)		 -5.23 -5.00 -4.97

Quarterly Balance Sheets for Altimmune

This table presents Altimmune's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 225 187 183 167 188 173 148
Total Current Assets		 211 173 170 153 188 171 146
Cash & Equivalents		 127 105 102 87 79 57 31
Restricted Cash		 0.03 0.03 0.04 0.04 0.04 0.04 0.04
Short-Term Investments		 74 61 58 54 103 108 108
Accounts Receivable		 0.63 0.25 0.14 0.88 0.31 0.42 0.43
Prepaid Expenses		 4.79 3.98 5.82 7.62 2.87 3.23 3.00
Other Current Assets		 3.72 3.12 3.58 3.65 2.27 2.59 2.91
Plant, Property, & Equipment, net		 1.17 1.01 0.88 0.77 0.54 0.48 0.45
Total Noncurrent Assets		 13 13 13 13 0.30 1.68 1.66
Other Noncurrent Operating Assets		 0.68 0.55 0.48 0.43 0.30 1.68 1.66
Total Liabilities & Shareholders' Equity		 225 187 183 167 188 173 148
Total Liabilities		 20 19 16 16 15 21 14
Total Current Liabilities		 16 15 11 12 11 15 8.64
Accounts Payable		 1.42 5.24 4.04 3.05 3.76 2.69 1.13
Accrued Expenses		 14 9.71 7.40 8.83 7.57 12 7.51
Total Noncurrent Liabilities		 4.51 4.40 4.17 4.31 4.09 5.66 5.85
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 205 168 168 150 173 153 133
Total Preferred & Common Equity		 205 168 168 150 173 153 133
Total Common Equity		 205 168 168 150 173 153 133
Common Stock		 567 571 587 590 669 673 676
Retained Earnings		 -356 -398 -414 -435 -491 -515 -538
Accumulated Other Comprehensive Income / (Loss)		 -5.30 -5.10 -5.18 -5.12 -5.16 -5.19 -4.85

Annual Metrics and Ratios for Altimmune

This table displays calculated financial ratios and metrics derived from Altimmune's official financial filings.

Metric 2022 2023 2024
Growth Metrics		 - - -
Revenue Growth		 -101.54% 726.47% -95.31%
EBITDA Growth		 9.06% -11.12% -9.19%
EBIT Growth		 9.78% -9.10% -7.69%
NOPAT Growth		 9.47% -9.33% -7.55%
Net Income Growth		 12.75% -4.41% -7.48%
EPS Growth		 22.98% 8.29% 19.28%
Operating Cash Flow Growth		 20.01% -21.13% -5.33%
Free Cash Flow Firm Growth		 30.93% -25.58% -9.00%
Invested Capital Growth		 -69.65% -87.08% -582.84%
Revenue Q/Q Growth		 -102.05% 52.69% -61.54%
EBITDA Q/Q Growth		 0.45% -15.49% 7.50%
EBIT Q/Q Growth		 0.85% -12.04% 7.91%
NOPAT Q/Q Growth		 1.01% -12.33% 7.82%
Net Income Q/Q Growth		 2.56% -12.72% 8.17%
EPS Q/Q Growth		 4.74% -5.06% 14.10%
Operating Cash Flow Q/Q Growth		 6.93% 1.01% -2.22%
Free Cash Flow Firm Q/Q Growth		 14.91% 4.78% -6.55%
Invested Capital Q/Q Growth		 -35.37% -95.38% -1,479.08%
Profitability Metrics		 - - -
Gross Margin		 0.00% 100.00% 100.00%
EBITDA Margin		 0.00% -22,947.65% -533,680.00%
Operating Margin		 0.00% -22,518.54% -515,860.00%
EBIT Margin		 0.00% -22,479.58% -515,620.00%
Profit (Net Income) Margin		 0.00% -20,762.21% -475,295.00%
Tax Burden Percent		 99.77% 100.00% 100.00%
Interest Burden Percent		 96.74% 92.36% 92.18%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -2,397.80% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -2,386.40% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 2,351.17% 0.00%
Return on Equity (ROE)		 -44.07% -46.63% -59.86%
Cash Return on Invested Capital (CROIC)		 -469.71% -2,243.57% 0.00%
Operating Return on Assets (OROA)		 0.00% -45.87% -58.94%
Return on Assets (ROA)		 0.00% -42.36% -54.33%
Return on Common Equity (ROCE)		 -44.07% -46.63% -59.86%
Return on Equity Simple (ROE_SIMPLE)		 -45.72% -45.57% -76.97%
Net Operating Profit after Tax (NOPAT)		 -61 -67 -72
NOPAT Margin		 0.00% -15,762.98% -361,102.00%
Net Nonoperating Expense Percent (NNEP)		 -12.83% -11.40% -14.27%
Return On Investment Capital (ROIC_SIMPLE)		 - -34.60% -58.47%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 4,257.51% 104,830.00%
R&D to Revenue		 0.00% 15,445.77% 411,130.00%
Operating Expenses to Revenue		 0.00% 22,618.54% 515,960.00%
Earnings before Interest and Taxes (EBIT)		 -88 -96 -103
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -88 -98 -107
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 4.36 3.11 4.15
Price to Tangible Book Value (P/TBV)		 4.68 3.11 4.15
Price to Revenue (P/Rev)		 0.00 1,418.90 25,640.43
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 125.76 634.31 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 954.45 19,043.78
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -0.94 -0.99 -1.01
Leverage Ratio		 1.11 1.10 1.10
Compound Leverage Factor		 1.07 1.02 1.02
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 19.49 18.45 12.48
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 11.31 17.26 13.11
Quick Ratio		 10.85 16.38 12.65
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -50 -63 -68
Operating Cash Flow to CapEx		 -49,671.43% -161,297.87% 0.00%
Free Cash Flow to Firm to Interest Expense		 -6,254.25 -1,795.18 -7,609.38
Operating Cash Flow to Interest Expense		 -7,823.25 -2,166.00 -8,872.00
Operating Cash Flow Less CapEx to Interest Expense		 -7,839.00 -2,167.34 -8,872.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.66 0.02
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.49 0.04
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 550.07 15,101.88
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 550.07 15,101.88
Capital & Investment Metrics		 - - -
Invested Capital		 4.96 0.64 -3.10
Invested Capital Turnover		 0.00 0.15 -0.02
Increase / (Decrease) in Invested Capital		 -11 -4.32 -3.74
Enterprise Value (EV)		 624 407 381
Market Capitalization		 809 604 513
Book Value per Share		 $3.77 $3.61 $1.74
Tangible Book Value per Share		 $3.52 $3.61 $1.74
Total Capital		 185 194 124
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -185 -198 -132
Capital Expenditures (CapEx)		 0.13 0.05 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9.16 -0.37 -5.15
Debt-free Net Working Capital (DFNWC)		 176 197 127
Net Working Capital (NWC)		 176 197 127
Net Nonoperating Expense (NNE)		 23 21 23
Net Nonoperating Obligations (NNO)		 -180 -193 -127
Total Depreciation and Amortization (D&A)		 -0.21 -1.99 -3.61
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -87.56% -25,735.00%
Debt-free Net Working Capital to Revenue		 0.00% 46,357.51% 633,930.00%
Net Working Capital to Revenue		 0.00% 46,357.51% 633,930.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($1.81) ($1.66) ($1.34)
Adjusted Weighted Average Basic Shares Outstanding		 46.93M 53.25M 71.00M
Adjusted Diluted Earnings per Share		 ($1.81) ($1.66) ($1.34)
Adjusted Weighted Average Diluted Shares Outstanding		 46.93M 53.25M 71.00M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 49.28M 70.90M 77.01M
Normalized Net Operating Profit after Tax (NOPAT)		 -61 -58 -72
Normalized NOPAT Margin		 0.00% -13,722.30% -361,102.00%
Pre Tax Income Margin		 0.00% -20,762.21% -475,295.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 -10,971.50 -2,736.09 -11,458.22
NOPAT to Interest Expense		 -7,677.25 -1,918.58 -8,024.49
EBIT Less CapEx to Interest Expense		 -10,987.25 -2,737.43 -11,458.22
NOPAT Less CapEx to Interest Expense		 -7,693.00 -1,919.92 -8,024.49
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Altimmune

This table displays calculated financial ratios and metrics derived from Altimmune's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -98.73% -103.36% -34.38% -25.00% 18,000.00% 133.64% -76.19% -16.67% -98.62% -86.49%
EBITDA Growth		 25.18% 4.58% -14.67% 9.44% 7.10% -49.61% -25.28% -51.25% -11.32% 25.30%
EBIT Growth		 26.24% 3.13% -12.13% 12.16% 8.81% -44.15% -23.30% -49.89% -9.87% 26.35%
NOPAT Growth		 25.45% 3.71% -11.59% 11.71% 8.94% -45.59% -23.14% -48.53% -9.88% 26.04%
Net Income Growth		 29.82% 9.33% -3.31% 20.12% 12.10% -46.08% -21.52% -53.42% -10.52% 26.74%
EPS Growth		 40.74% 16.07% 9.09% 23.81% 18.75% -17.02% 15.00% -9.38% 17.95% 40.00%
Operating Cash Flow Growth		 15.33% 21.22% -43.48% -16.04% -36.13% 4.47% 15.72% 6.58% -32.37% -10.48%
Free Cash Flow Firm Growth		 64.18% 77.64% -270.34% -2,477.72% -56.05% -301.88% 31.56% 99.40% 85.18% 28.86%
Invested Capital Growth		 -29.67% -69.65% -41.38% 5.44% 80.90% -87.08% -179.13% -156.87% -101.41% -582.84%
Revenue Q/Q Growth		 -75.00% -5,600.00% 119.09% -71.43% 5,933.33% -89.78% -86.49% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -22.28% 8.03% 3.30% 16.73% -25.43% -48.12% 12.71% -0.53% 7.68% 0.61%
EBIT Q/Q Growth		 -21.27% 5.63% 6.74% 17.69% -25.89% -49.17% 20.23% -0.06% 7.73% 0.00%
NOPAT Q/Q Growth		 -21.36% 6.70% 5.78% 17.24% -25.17% -49.17% 20.31% 0.18% 7.40% -0.40%
Net Income Q/Q Growth		 -16.95% 7.89% 7.32% 19.99% -28.70% -53.07% 22.90% -1.01% 7.28% -1.47%
EPS Q/Q Growth		 -14.29% 2.08% 14.89% 20.00% -21.88% -41.03% 38.18% -2.94% 8.57% -3.13%
Operating Cash Flow Q/Q Growth		 9.90% -14.99% -12.14% 0.12% -5.70% 19.30% 1.06% -10.70% -49.76% 32.65%
Free Cash Flow Firm Q/Q Growth		 -2,647.64% 66.06% -124.50% -23.13% -66.34% 12.59% 61.77% 98.92% -3,999.25% -319.47%
Invested Capital Q/Q Growth		 -31.91% -35.37% 28.41% 86.59% 16.81% -95.38% -886.27% -34.09% 97.10% -1,479.08%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -1,242,150.00% 0.00% -105,219.05% -306,650.00% -6,375.14% -92,389.19% -553,640.00% -556,580.00% -513,820.00% -510,680.00%
Operating Margin		 -1,237,600.00% 0.00% -103,614.29% -300,116.67% -6,226.52% -90,872.97% -535,880.00% -534,900.00% -495,340.00% -497,320.00%
EBIT Margin		 -1,235,100.00% 0.00% -103,523.81% -298,233.33% -6,222.65% -90,818.92% -536,120.00% -536,420.00% -494,980.00% -494,960.00%
Profit (Net Income) Margin		 -1,175,800.00% 0.00% -95,590.48% -267,683.33% -5,710.22% -85,516.22% -487,880.00% -492,800.00% -456,900.00% -463,600.00%
Tax Burden Percent		 99.17% 100.00% 0.00% 0.00% 100.00% 46.68% 0.00% 0.00% 100.00% 32.10%
Interest Burden Percent		 96.00% 92.92% 0.00% 0.00% 91.77% 201.70% 0.00% 0.00% 92.31% 291.80%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -309,420.06% 0.00% 0.00% 0.00% -112.83% -9,676.24% -231,448.55% -59,751.02% -2,634.86% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -309,416.93% 0.00% 0.00% 0.00% -109.90% -9,671.91% -231,445.22% -59,747.27% -2,630.79% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 295,536.48% 0.00% 0.00% 0.00% 103.23% 9,529.12% 230,542.32% 58,790.92% 2,503.91% 0.00%
Return on Equity (ROE)		 -13,883.58% -44.07% -48.42% -44.89% -9.60% -147.12% -906.23% -960.10% -130.96% -59.86%
Cash Return on Invested Capital (CROIC)		 -632.81% -469.71% -678.94% -535.02% -612.25% -2,243.57% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -17,738.82% 0.00% 0.00% 0.00% -8.86% -185.31% -1,170.94% -1,230.27% -163.71% -56.58%
Return on Assets (ROA)		 -16,887.14% 0.00% 0.00% 0.00% -8.13% -174.49% -1,065.58% -1,130.23% -151.12% -52.99%
Return on Common Equity (ROCE)		 -13,883.58% -44.07% -48.42% -44.89% -9.60% -147.12% -906.23% -960.10% -130.96% -59.86%
Return on Equity Simple (ROE_SIMPLE)		 -42.40% 0.00% -50.89% -48.48% -52.17% 0.00% -53.64% -66.44% -77.61% 0.00%
Net Operating Profit after Tax (NOPAT)		 -17 -16 -15 -13 -16 -24 -19 -19 -17 -17
NOPAT Margin		 -866,320.00% 0.00% -72,530.00% -210,081.67% -4,358.56% -63,611.08% -375,116.00% -374,430.00% -346,738.00% -348,124.00%
Net Nonoperating Expense Percent (NNEP)		 -3.13% -3.03% -2.89% -2.04% -2.93% -4.34% -3.32% -3.76% -4.08% -3.61%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -12.13% - - - -14.09%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 224,600.00% 0.00% 21,576.19% 79,333.33% 1,246.96% 11,708.11% 106,240.00% 111,900.00% 99,380.00% 101,800.00%
R&D to Revenue		 1,013,100.00% 0.00% 82,138.10% 220,883.33% 5,079.56% 45,700.00% 429,740.00% 423,100.00% 396,060.00% 395,620.00%
Operating Expenses to Revenue		 1,237,700.00% 0.00% 103,714.29% 300,216.67% 6,326.52% 90,972.97% 535,980.00% 535,000.00% 495,440.00% 497,420.00%
Earnings before Interest and Taxes (EBIT)		 -25 -23 -22 -18 -23 -34 -27 -27 -25 -25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -25 -23 -22 -18 -23 -34 -28 -28 -26 -26
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 3.02 4.36 1.24 1.04 0.91 3.11 4.17 3.09 3.27 4.15
Price to Tangible Book Value (P/TBV)		 3.22 4.68 1.34 1.12 0.99 3.11 4.17 3.09 3.27 4.15
Price to Revenue (P/Rev)		 186.74 0.00 0.00 0.00 490.98 1,418.90 1,760.28 1,152.81 8,391.84 25,640.43
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 55.05 125.76 7.32 1.53 0.03 634.31 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 127.28 0.00 0.00 0.00 1.68 954.45 1,316.22 749.51 5,710.65 19,043.78
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.02 0.00 0.03 0.02 0.03 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.02 0.00 0.03 0.02 0.03 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.96 -0.94 -0.95 -0.94 -0.94 -0.99 -1.00 -0.98 -0.95 -1.01
Leverage Ratio		 1.12 1.11 1.11 1.09 1.10 1.10 1.10 1.11 1.11 1.10
Compound Leverage Factor		 1.07 1.03 0.00 0.00 1.01 2.22 0.00 0.00 1.02 3.22
Debt to Total Capital		 2.15% 0.00% 2.56% 2.42% 2.78% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 2.15% 0.00% 2.56% 2.42% 2.78% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 97.85% 100.00% 97.44% 97.58% 97.22% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.05 0.00 -0.05 -0.05 -0.05 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 2.23 0.00 1.80 1.79 1.61 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.05 0.00 -0.05 -0.05 -0.05 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.07 0.00 -0.07 -0.07 -0.07 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 3.18 0.00 2.56 2.54 2.28 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.07 0.00 -0.07 -0.07 -0.07 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 16.85 20.52 4.10 4.24 2.00 19.43 25.09 10.00 13.54 14.34
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 13.40 11.31 11.58 14.82 12.89 17.26 16.55 11.30 16.87 13.11
Quick Ratio		 12.86 10.85 11.10 14.00 11.93 16.38 16.09 10.91 16.19 12.65
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -14 -4.78 -11 -13 -22 -19 -7.35 -0.08 -3.26 -14
Operating Cash Flow to CapEx		 -25,083.33% -45,542.11% -38,052.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -220.14 0.00 -5,367.65 0.00 -758.14 0.00 -7,346.80 0.00 -543.15 0.00
Operating Cash Flow to Interest Expense		 -235.16 0.00 -9,703.50 0.00 -706.45 0.00 -16,357.00 0.00 -4,519.67 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -236.09 0.00 -9,729.00 0.00 -706.45 0.00 -16,357.00 0.00 -4,519.67 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 3.01 0.00 0.00 0.00 0.37 0.66 1.47 1.46 0.08 0.02
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.13 0.00 0.00 0.00 0.29 0.49 0.53 0.60 0.09 0.04
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 121.34 0.00 0.00 0.00 987.07 550.07 248.82 249.88 4,576.54 15,101.88
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 121.34 0.00 0.00 0.00 987.07 550.07 248.82 249.88 4,576.54 15,101.88
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 7.67 4.96 6.37 12 14 0.64 -5.04 -6.76 -0.20 -3.10
Invested Capital Turnover		 0.36 0.00 0.00 0.00 0.03 0.15 0.62 0.16 0.01 -0.02
Increase / (Decrease) in Invested Capital		 -3.24 -11 -4.50 0.61 6.21 -4.32 -11 -19 -14 -3.74
Enterprise Value (EV)		 422 624 47 18 0.47 407 540 307 297 381
Market Capitalization		 620 809 208 174 137 604 722 471 436 513
Book Value per Share		 $4.22 $3.77 $3.40 $3.40 $2.85 $3.61 $2.44 $2.15 $1.88 $1.74
Tangible Book Value per Share		 $3.97 $3.52 $3.15 $3.15 $2.62 $3.61 $2.44 $2.15 $1.88 $1.74
Total Capital		 210 185 172 172 155 194 173 153 133 124
Total Debt		 4.51 0.00 4.40 4.17 4.31 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 4.51 0.00 4.40 4.17 4.31 0.00 0.00 0.00 0.00 0.00
Net Debt		 -197 -185 -161 -156 -137 -198 -182 -165 -139 -132
Capital Expenditures (CapEx)		 0.06 0.04 0.05 -0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.60 -9.16 -7.60 -1.90 0.27 -0.37 -5.88 -8.92 -2.30 -5.15
Debt-free Net Working Capital (DFNWC)		 195 176 158 158 141 197 176 156 137 127
Net Working Capital (NWC)		 195 176 158 158 141 197 176 156 137 127
Net Nonoperating Expense (NNE)		 6.19 5.49 4.84 3.46 4.89 8.10 5.64 5.92 5.51 5.77
Net Nonoperating Obligations (NNO)		 -197 -180 -161 -156 -137 -193 -178 -159 -134 -127
Total Depreciation and Amortization (D&A)		 -0.14 0.46 -0.36 -0.51 -0.55 -0.58 -0.88 -1.01 -0.94 -0.79
Debt-free, Cash-free Net Working Capital to Revenue		 -198.82% 0.00% 0.00% 0.00% 97.85% -87.56% -1,434.88% -2,180.44% -4,425.00% -25,735.00%
Debt-free Net Working Capital to Revenue		 5,883.16% 0.00% 0.00% 0.00% 50,570.97% 46,357.51% 42,971.22% 38,149.39% 263,694.23% 633,930.00%
Net Working Capital to Revenue		 5,883.16% 0.00% 0.00% 0.00% 50,570.97% 46,357.51% 42,971.22% 38,149.39% 263,694.23% 633,930.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.48) ($0.47) ($0.40) ($0.32) ($0.39) ($0.55) ($0.34) ($0.35) ($0.32) ($0.33)
Adjusted Weighted Average Basic Shares Outstanding		 49.29M 46.93M 50.13M 50.69M 53.63M 53.25M 70.80M 70.92M 71.08M 71.00M
Adjusted Diluted Earnings per Share		 ($0.48) ($0.47) ($0.39) ($0.32) ($0.39) ($0.55) ($0.34) ($0.35) ($0.32) ($0.33)
Adjusted Weighted Average Diluted Shares Outstanding		 49.29M 46.93M 50.13M 50.69M 53.63M 53.25M 70.80M 70.92M 71.08M 71.00M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 49.16M 49.28M 49.29M 52.69M 53.73M 70.90M 70.90M 71.07M 71.12M 77.01M
Normalized Net Operating Profit after Tax (NOPAT)		 -17 -16 -15 -13 -16 -24 -19 -19 -17 -17
Normalized NOPAT Margin		 -866,320.00% 0.00% -72,530.00% -210,081.67% -4,358.56% -63,611.08% -375,116.00% -374,430.00% -346,738.00% -348,124.00%
Pre Tax Income Margin		 -1,185,650.00% 0.00% 0.00% 0.00% -5,710.22% -183,178.38% 0.00% 0.00% -456,900.00% -1,444,280.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -385.97 0.00 -10,870.00 0.00 -776.76 0.00 -26,806.00 0.00 -4,124.83 0.00
NOPAT to Interest Expense		 -270.73 0.00 -7,615.65 0.00 -544.07 0.00 -18,755.80 0.00 -2,889.48 0.00
EBIT Less CapEx to Interest Expense		 -386.91 0.00 -10,895.50 0.00 -776.76 0.00 -26,806.00 0.00 -4,124.83 0.00
NOPAT Less CapEx to Interest Expense		 -271.66 0.00 -7,641.15 0.00 -544.07 0.00 -18,755.80 0.00 -2,889.48 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Altimmune's Financials

When does Altimmune's fiscal year end?

According to the most recent income statement we have on file, Altimmune's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Altimmune's net income changed over the last 2 years?

Altimmune's net income appears to be on an upward trend, with a most recent value of -$95.06 million in 2024, rising from -$84.71 million in 2022. The previous period was -$88.45 million in 2023.

What is Altimmune's operating income?
Altimmune's total operating income in 2024 was -$103.17 million, based on the following breakdown:
  • Total Gross Profit: $20 thousand
  • Total Operating Expenses: $103.19 million
How has Altimmune revenue changed over the last 2 years?

Over the last 2 years, Altimmune's total revenue changed from -$68 thousand in 2022 to $20 thousand in 2024, a change of -129.4%.

How much debt does Altimmune have?

Altimmune's total liabilities were at $15.80 million at the end of 2024, a 4.5% decrease from 2023, and a 27.0% decrease since 2022.

How much cash does Altimmune have?

In the past 2 years, Altimmune's cash and equivalents has ranged from $36.93 million in 2024 to $135.12 million in 2023, and is currently $36.93 million as of their latest financial filing in 2024.

How has Altimmune's book value per share changed over the last 2 years?

Over the last 2 years, Altimmune's book value per share changed from 3.77 in 2022 to 1.74 in 2024, a change of -53.9%.


Related Companies

This page (NASDAQ:ALT) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners
Feds Just Admitted It—They Can Take Your Cash
Here’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...
Priority Gold | Sponsored
Trump Orders 'National Digital Asset Stockpile'
‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more traction
Crypto 101 Media | Sponsored
M.A.G.A. is Finished – This Could be even Better
You’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...
Paradigm Press | Sponsored
The Exact July Date the AI Correction Will End?
AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...
Brownstone Research | Sponsored
This Is The Moment You Betray Trump (Or Prove Them Wrong)
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...
Colonial Metals | Sponsored
Virtually Limitless Energy?
A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...
Stansberry Research | Sponsored
Trump’s treachery
Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...
Porter & Company | Sponsored